Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Letrozole - Novartis

Drug Profile

Letrozole - Novartis

Alternative Names: CGP 20267; CGS 20267; Femara

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Eli Lilly and Company; Gynecologic Oncology Group; M. D. Anderson Cancer Center; National Cancer Institute (USA); Novartis; SOLTI Breast Cancer Research Group; University of Colorado at Denver
  • Class Antineoplastics; Infertility therapies; Nitriles; Small molecules; Triazoles
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III HER2 negative breast cancer
  • Phase II Endometrial cancer; Fallopian tube cancer; Leiomyosarcoma; Ovarian cancer; Peritoneal cancer
  • Discontinued Delayed puberty; Endometriosis; Female infertility

Most Recent Events

  • 10 May 2023 Novartis Pharmaceuticals completes a phase II RIGHT Choice trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Egypt, India, Jordan, Lebanon, Russian Federation, Saudi Arabia, Singapore, South Africa, Thailand, Turkey, Taiwan, Malaysia, Vietnam(PO) (NCT03839823)
  • 28 Mar 2023 Efficacy data from a phase II trial in Fallopian tube cancer released by Mount Sinai Medical Center
  • 28 Mar 2023 Mount Sinai Medical Center plans a head-to-head study of ribociclib and letrozole vs the best current therapies
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top